TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05046132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Administered once daily via SC injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin capsules via oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin capsules via oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Placebo capsules via oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: Placebo capsules via oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: Placebo capsules via oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SC Placebo
Description: Placebo via SC injection.
Study: NCT04790773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amazon Alexa based voice recording patient education
Description: Amazon Alexa based voice recording of medication education material
Study: NCT05046132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SC Placebo
Description: Placebo via SC injection.
Study: NCT05292638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKDB-501A
Description: Intramuscular injection CKDB-501A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: Intramuscular injection Botox®
Study: NCT05345561

Intervention type: OTHER
Intervention: Clinical data collection
Description: Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.
Study: NCT05247034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: Each capsule of cocoa powder contains 12.5 mg of flavonoids, providing a total of 50 mg per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each capsule contains 500 mg of methylcellulose
Study: NCT05112861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 1.25 mg, intravitreal injection
Study: NCT05837390

Intervention type: DEVICE
Intervention: Cervical stiffness assessment
Description: The cervical stiffness is assessed by using the licensed, CE-marked Pregnolia System, during a sterile speculum examination. The single-use, sterile Pregnolia Probe is placed on the anterior lip of the cervix at 12 o'clock position and a recording of cervical stiffness is generated over maximum 60 seconds (typically ̴15 seconds) and displayed as Cervical Stiffness Index (CSI) in mbar. The measurement is repeated 3 consecutive times without any time lag.

Intervention type: OTHER
Intervention: Cervical length measurement
Description: Cervical length measurement will be obtained via transvaginal ultrasound using a GE Voluson E10 ultrasound machine and 7.5MHz transvaginal probe. All measurements will be performed with the woman in a supine position with an empty bladder in the sagittal plane measuring from the internal to external cervical OS. The full length of the cervical canal will be visualized with the closed portion of cervix remaining being measured. Three measurements are taken with the shortest being documented as the final assessment.

Intervention type: OTHER
Intervention: Fetal fibronectin
Description: Vaginal swab collection. The specimen will be obtained from the posterior fornix over 10 seconds using the polyester tipped swab provided in the Hologic specimen collection kit. This sample will be then be stored frozen and processed using the Rapid fFN 10Q System (HOLOGIC, Marlborough, MA, USA) within 3 months.
Study: NCT05318573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832
Description: Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832
Description: Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832
Description: Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832
Description: Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10832
Description: Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT05859971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLN mapping using technetium-99m +/- isosulfan blue dye
Description: The isosulfan blue dye injection will be performed by the participating surgeon in the operating room; as per standard of care, injection will be subareolar. Incisions will be planned based on the technetium-99m activity or at the lateral aspect of the pectoralis muscle, per usual care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLN mapping with ICG fluorescence using the Asimov Platform
Description: 2 ml (5 mg) of ICG solution will be injected intradermally in 1-4 injection sites in the lateral areolar region. After injection, gentle manual massage will be performed for 5 minutes. ICG imaging will be obtained prior to incision. After incision is made (following standard of care procedures), the axilla will be visualized using the Asimov Platform to assess for ICG-fluorescence in sentinel lymph nodes.
Study: NCT05875350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraligamental local anesthetic injection
Description: The intraligamental technique was administered using ligajet intraligamentary jet injector (Micro Mega Company) containing Articaine hydrochloride 4% with adrenaline 1:200000 (ArtPharma Dent, inc, Egypt)
Study: NCT06454734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy by radial device
Description: Patients will receive treatment by extracorporeal shock waves therapy (ESWT).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo extracorporeal shock wave therapy by radial device
Description: Patients will receive treatment sham extracorporeal shock waves.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DLT
Description: Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DLT
Description: Patients will receive treatment with decongestive lymphatic therapy (DLT: manual lymphatic drainage, compression)
Study: NCT05001750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long term prophylactic antibiotics (Nafcillin or Doxycycline)
Description: VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain IRB NUMBER: 2021-12680 IRB APPROVAL DATE: 06/14/2021 NOABX in EVD Study 3 (EVD).
Study: NCT05300399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: The local healthcare providers will be assigned to an intervention group receiving the mHealth app to be used in their daily practices or a control group.
Study: NCT04867291

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pizza
Description: Portion equivalent to 200 µg of iodine (half a pizza), consumed with \~450mL of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed Sheets
Description: Portion equivalent to 200 µg of iodine (\~10g), consumed with two slices of white bread and \~450mL of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed Powder
Description: Portion equivalent to 200 µg of iodine (1 capsule), consumed with two slices of white bread and \~450mL of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium iodide
Description: Portion equivalent to 200 µg of iodine (1.3 tablets), consumed with two slices of white bread and \~450mL of water.
Study: NCT05818904

Intervention type: OTHER
Intervention: Physical Therapy
Description: All arthrosis participants will be treated as the traditional methods using physical therapy.

Intervention type: OTHER
Intervention: Physical Therapy
Description: All arthrosis participants will be treated as the traditional methods using physical therapy.
Study: NCT06425068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exposure of the patient to a novel air mattress.
Description: see information provided in the Arms section (experimental)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exposure of the patient to a conventional foam mattress.
Description: see information provided in the Arms section (active comparator)
Study: NCT06273657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medisinstart
Description: Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.
Study: NCT06231199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastrocnemius release
Description: The patient will be prone to lying and the therapist will stand at the side of the patient's leg. The therapist uses both hands in cross-hand pattern (Figure 10a and 10b). Myofascial Release will be performed for 20 repetitions, then gastrocnemius release by foam roller;This involved long sitting, with the affected leg will be extended on the foam roller and foot relaxed. The non-affected leg will be flexed at knee so that the foot will be rested on the floor. The participants will be instructed to use their arms and non_affected foot to propel their body back and forth from the popliteal fossa to Achilles tendon in continuous motion. then patients perform plantar fascia realise from standing by foam roller

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive conventional treatment in the form of ultrasound therapy (continuous mode/1MHZ) followed by plantar fascia stretch and inctruction
Study: NCT06072001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adezunap (AP707)
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT04961372

Intervention type: OTHER
Intervention: Survey
Description: PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment

Intervention type: OTHER
Intervention: Survey
Description: PHQ9 Depression Scale for evaluating depression, GAD7 Anxiety Score for evaluating anxiety, WSAS Score for evaluating Work and Social Adjustment
Study: NCT04955119

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fusion imaging contrast-enhanced ultrasound
Description: Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.~Drug: SonoVue
Study: NCT04925739

Intervention type: OTHER
Intervention: Self-questionnaire on the comfort and general appreciation of a nasal mask
Description: Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use

Intervention type: OTHER
Intervention: Self-questionnaire on the appearance of CPAP side effects related to the mask
Description: Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use

Intervention type: OTHER
Intervention: Self-questionnaire on the patient's appreciation of the mask headgear,
Description: Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use.

Intervention type: OTHER
Intervention: Self-questionnaire NOSE on the discomfort caused by the nasal obstruction
Description: Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion.

Intervention type: OTHER
Intervention: Self-questionnaire Epworth on the daytime sleepiness
Description: Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion.~To study the parameters of the CPAP treatment.

Intervention type: OTHER
Intervention: To study the CPAP compliance
Description: To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment.
Study: NCT05349734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overbody blanket
Description: applying overbody blanket with forced-air blower set to 43℃

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: underbody blanket
Description: applying underbody blanket with forced-air blower set to 43℃
Study: NCT05023109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP+PD-1+Tight
Description: Drug: Tislelizumab Tislelizumab 200mg IV Q3W~Other Name:~BGB-A317 Anti-PD-1 therapy~Drug: Ociperlimab Ociperlimab 900mg IV Q3W~Other Name:~BGB-A1217 Anti-TIGIT therapy~Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W
Study: NCT05445609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLP-encapsulated TLR9 Agonist CMP-001,
Description: Given SC or IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05787834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear accelerometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear accelerometer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Training
Description: Undergo RMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training
Description: Undergo RMT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04925739

Intervention type: OTHER
Intervention: To study the unintentional leakage
Description: To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment.

Intervention type: OTHER
Intervention: To study the therapeutic pressures of CPAP
Description: To collect the therapeutic pressures of CPAP, during the 30 days of treatment.
Study: NCT05270551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: All participants will do ACL reconstruction with and without Augmentation and will receive Accelerated rehabilitation program
Study: NCT05117372

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment with immunotherapy and diffuse infiltrative lung disease
Description: Patients treated with with immunotherapy and developing diffuse infiltrative lung disease

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patients requiring carcinologic lobectomy
Description: Patients requiring carcinologic lobectomy
Study: NCT05941949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E
Description: 2 softgels per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 softgels per day
Study: NCT06060223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach Back Method
Description: Training and consultancy services based on the teach-back method will be provided to individuals in the training group using the Heart Failure Training Guide in the form of 3 follow-ups in the cardiology clinic and telephone counseling. Telephone interviews were conducted by the researcher in the first week after discharge, it will be held in the first month and 3rd month. In addition, patients will receive counseling by calling the researcher if necessary.
Study: NCT06553417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqua posae and microresyl
Description: * This intervention involves the use of two topical products:~  * Aqua posae - a moisturizing agent~ * Microresyl - an active ingredient with potential therapeutic effects~* Subjects in Group A will be instructed to apply these two products (aqua posae and microresyl) twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urea 10%
Description: Intervention 2: Urea 10%~* This intervention involves the use of a 10% urea-based topical moisturizing product.~* Subjects in Group B will be instructed to apply the 10% urea moisturizer twice daily to the upper and lower limbs, including both lesional and non-lesional areas of the skin.~The use of these interventions will be evaluated over a 12-week period, with assessments of Transepidermal Water Loss (TEWL), skin hydration, skin pH, index scoring of atopic dermatitis (SCORAD), erythema area severity index (EASI), pruritus visual analogue scale (PVAS), quality of life (DLQI), and any adverse effects.
Study: NCT05772871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaiqihuang granule
Description: Huaiqihuang Granule, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
Study: NCT05662137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotions Recognition and Expression
Description: Emotion recognition and expression program consisting of 8 sessions will be used. In this program, patients will have the opportunity to describe their emotions, explain emotions that are difficult to express such as anger, sadness, shame, guilt, and discuss the consequences of suppressed emotions.
Study: NCT05826951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol (0.8g/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol (0.8g/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05772871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole placebo
Description: Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levamisole
Description: Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huaiqihuang Granule placebo
Description: Huaiqihuang Granule placebo, oral administration, recommended daily dose: for body weight \<10 kg, 5g, twice a day; for 10 kg ≤ body weight \<20 kg, 10g, twice a day; for 20 kg≤body weight \<30 kg, 15g, twice a day; for 30 kg≤body weight \<50 kg, 20g, twice a day; for body weight\>50 kg, 30g, twice a day. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.